Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 18/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19431000 | 0.86 | SCN9A (0.42) | SCN9ASCN1ASCN4ASCN7ASCN5A | |
| SCHEMBL20910878 | 0.84 | SCN9A (0.57) | SCN9ASCN1ASCN7ASCN5ASCN2A | |
| SCHEMBL19411371 | 0.80 | SCN9A (0.54) | SCN9ASCN7ASCN5A | |
| SCHEMBL19411381 | 0.78 | SCN9A (0.54) | SCN9A | |
| SCHEMBL19411416 | 0.78 | SCN9A (0.50) | SCN9A | |
| SCHEMBL19427304 | 0.73 | SCN9A (0.48) | SCN9ASCN1ASCN4ASCN7ASCN5A | |
| SCHEMBL20910575 | 0.72 | SCN9A (0.71) | SCN9ASCN1ASCN4ASCN7ASCN5A | |
| SCHEMBL19430742 | 0.70 | SCN9A (0.57) | SCN9ASCN1ASCN7ASCN5ASCN2A | |
| SCHEMBL20910585 | 0.67 | SCN9A (0.67) | SCN9ASCN1ASCN4ASCN7ASCN5A | |
| SCHEMBL20910730 | 0.67 | SCN9A (0.54) | SCN9ASCN1ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203572-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210155588-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-05-27 | — | — | US | disclosed |
| US-10766858-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190112264-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155588-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | SCN9A 1549/4885SCN1A 284/4885SCN4A 362/4885 |
| US-11203572-B2 | Substituted benzamides and methods of use thereof | BRIX1, RDX, RRM1 | SCN9A 1549/4885SCN1A 284/4885SCN4A 362/4885 |
| US-20190112264-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | SCN9A 1547/4885SCN1A 266/4885SCN4A 383/4885 |
| US-10766858-B2 | Substituted benzamides and methods of use thereof | BRIX1, RDX, SULT2A1 | SCN9A 1547/4885SCN1A 266/4885SCN4A 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.